Klivira
Request demo

Navigating Aetna Epclusa Prior Authorization

Streamlining Aetna Epclusa prior authorization is critical for timely patient access to this high-volume specialty medication. Klivira automates the complex submission and tracking processes.

For revenue cycle directors and prior authorization teams, managing specialty drug approvals like Epclusa with a national payer like Aetna (CVS Aetna) presents unique challenges. Understanding Aetna's specific submission channels, policy requirements, and communication protocols is essential to minimize delays and reduce administrative burden, particularly for Hepatitis C treatments.

Aetna Epclusa Prior Authorization Submission Channels

Aetna's prior authorization submission channels for specialty drugs like Epclusa depend on whether the medication falls under the pharmacy or medical benefit. For pharmacy-benefit Epclusa, submissions route through CVS Caremark, Aetna's PBM, often via ePA partners like CoverMyMeds or Surescripts. Medical-benefit Epclusa requests are typically handled through the Availity provider portal or via X12 278 transactions through clearinghouses, with specific workflows for specialty pharmacy management.

Understanding Aetna's Medical Necessity Criteria for Epclusa

Aetna publishes its medical necessity criteria for medications such as Epclusa in its Clinical Policy Bulletins (CPBs), accessible through the public Aetna CPB library. These CPBs are versioned and dated, providing the canonical identifier for all policy citations. For Epclusa, these policies will outline specific indications, dosing, duration of therapy, and any step-therapy requirements or preceding therapies that must be documented for approval.

Common Denial Reasons and Appeal Pathways for Epclusa with Aetna

Common reasons for Aetna Epclusa prior authorization denials often include insufficient documentation of medical necessity, failure to meet step-therapy requirements, or off-label use without compendium support. Denial reasons are communicated via X12 835/277 transactions or portal updates, leveraging CARC and RARC codes. Aetna's appeal pathway typically includes reconsideration, peer-to-peer review, and formal appeals, with expedited options available for urgent cases, as detailed in their provider manual.

Aetna's Prior Authorization Turnaround Times and Regulatory Impact

Aetna's prior authorization turnaround times are governed by state-mandated minimums for commercial plans and payer-published service-level targets. For Medicare Advantage and Medicaid managed-care plans (Aetna Better Health), Aetna is an impacted payer under CMS-0057-F, requiring 72-hour decisions for standard PA requests and 24-hour for expedited, with phased compliance through 2027. Commercial lines of business are not directly impacted by CMS-0057-F.

Leveraging Klivira for Aetna Epclusa PA Automation

Klivira integrates directly with your EMR system and Aetna's various submission channels, automating the submission and tracking of Epclusa prior authorizations. Our platform streamlines documentation gathering, ensures adherence to Aetna's Clinical Policy Bulletins, and provides real-time status updates, significantly reducing manual effort and improving turnaround times for critical Hepatitis C treatments.

Frequently asked questions

Which Aetna benefit typically covers Epclusa: pharmacy or medical?

The benefit that covers Epclusa (sofosbuvir/velpatasvir) with Aetna depends on the specific plan design and therapeutic category assignment. It can fall under either the pharmacy benefit, managed by CVS Caremark, or the medical benefit, managed through a specialty-pharmacy-management workflow. Providers should verify the benefit category for each patient's specific Aetna plan.

How do I submit an Epclusa prior authorization to Aetna?

For pharmacy-benefit Epclusa, submissions are typically routed through CVS Caremark, Aetna's PBM, using ePA platforms like CoverMyMeds or Surescripts. If Epclusa is covered under the medical benefit, prior authorization requests are commonly submitted via the Availity provider portal or through X12 278 electronic transactions via clearinghouses. Always confirm the correct channel based on the patient's plan and benefit design.

Where can I find Aetna's medical necessity criteria for Epclusa?

Aetna publishes its medical necessity criteria for medications like Epclusa in its Clinical Policy Bulletins (CPBs). These CPBs are publicly available in the Aetna CPB library. When citing policy, it is crucial to reference the specific CPB number and its effective date to ensure accuracy.

What are common reasons Aetna denies Epclusa prior authorizations?

Common denial reasons for Epclusa prior authorizations from Aetna include insufficient documentation to demonstrate medical necessity, failure to meet specific step-therapy protocols outlined in their CPBs, or requests for off-label use without adequate supporting clinical evidence. Denials are communicated with standard CARC and RARC codes.

Does CMS-0057-F directly impact Aetna Epclusa PAs for commercial plans?

No, CMS-0057-F directly impacts Aetna's Medicare Advantage, Medicaid managed-care (Aetna Better Health), CHIP managed-care, and Qualified Health Plan (QHP) lines of business. Aetna's commercial lines of business are not directly subject to the specific electronic prior authorization API requirements or decision timeframes mandated by CMS-0057-F, though state regulations still apply.

Related coverage

Other epclusa prior authorization by payer

Other epclusa prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo